Announcements Trials
Browse Landscape

Phase

Phase 3 18Phase 2 17Phase 1/2 5Phase 1 4Phase 4 2Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiosurgery 6pembrolizumab 5Oncolytic Virotherapy 4Magnetic Resonance Spectroscopy 4Fluorodeoxyglucose F18 4Carboplatin 4Paclitaxel 3Cyclophosphamide 3Cisplatin 3osimertinib 2atezolizumab 2aldesleukin 2Tobacco Use Cessation Devices 2Specimen Handling 2Radiotherapy 2Positron-Emission Tomography 2Pemetrexed 2Nivolumab 2Docetaxel 2toripalimab 1sugemalimab 1sodium thiosulfate 1perflutren 1palbociclib 1icotinib 1gallium 68 PSMA-11 1fludarabine 1durvalumab 1dapagliflozin 1dacomitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Crizotinib × Thoracic × Clear all
NCT02277457 2016-06-24

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡